Hepatoprotective Effects of β-Caryophyllene and Full-Spectrum Cannabis Extract Against Paracetamol-Induced Liver Injury in Mice
Article Sidebar
Main Article Content
Abstract
Background: Paracetamol overdose is a leading cause of acute liver injury. N-acetylcysteine (NAC) is the standard treatment but has limitations, including adverse reactions. Cannabis-derived compounds, particularly β-caryophyllene (BCP), have demonstrated anti-inflammatory and antioxidant effects through CB2 receptor activation.
Objectives: This study aimed to (i) determine the concentrations of cannabinoid constituents in commercially available Cannabis sativa samples and (ii) evaluate the efficacy of BCP and full-spectrum cannabis extract in mitigating paracetamol-induced hepatotoxicity in mice.
Methods: Four cannabis samples were analysed by GC-MS. Forty-two male albino mice were divided into seven groups, including negative and positive controls, paracetamol toxicity, BCP and cannabis treatment groups, and combination treatment groups. Serum ALT and AST levels were measured, and liver tissues were assessed histologically using hematoxylin–eosin staining. Statistical analysis was performed using t-tests and ANOVA with LSD post hoc tests.
Results: GC–MS analysis identified distinct cannabinoid profiles among the investigated cannabis samples, indicating differences in their phytochemical composition. In vivo, administration of β-caryophyllene (BCP) and full-spectrum cannabis extract significantly attenuated paracetamol-induced hepatotoxicity, as demonstrated by reduced serum ALT and AST levels compared with the untreated paracetamol group (p ≤ 0.05).
Histological assessment corroborated these findings, revealing improved hepatic architecture in both treated groups. Importantly, the BCP-treated group exhibited a more pronounced hepatoprotective effect, characterised by greater normalisation of liver enzyme levels and enhanced preservation of liver histoarchitecture relative to the full-spectrum extract.
Conclusion: Both β-caryophyllene and full-spectrum cannabis extract exhibit significant hepatoprotective properties against paracetamol-induced liver injury. β-caryophyllene, however, demonstrated superior efficacy across biochemical and histopathological parameters, underscoring its potential as a therapeutic agent. These findings support further experimental and clinical investigations to explore its mechanism of action and potential applications in liver disease management.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
J. R. Mitchell, D. J. Jollow, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie, “Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism.,” J. Pharmacol. Exp. Ther., vol. 187, no. 1, pp. 185–194, 1973.
J. A. Hinson, D. W. Roberts, and L. P. James, “Mechanisms of Acetaminophen-Induced Liver Necrosis,” in Handbook of Experimental Pharmacology, vol. 196, 2010, pp. 369–405. doi: 10.1007/978-3-642-00663-0_12.
P. Ging, O. Mikulich, and K. M. A. O’Reilly, “Unexpected paracetamol (acetaminophen) hepatotoxicity at standard dosage in two older patients: time to rethink 1 g four times daily?: Table 1.,” Age Ageing, vol. 45, no. 4, pp. 566–567, 2016, doi: 10.1093/ageing/afw067.
M. R. M. Hartmut Jaeschke Anup Ramachandran, “Oxidant stress and mechanisms of drug-induced liver injury,” Gastroenterology, vol. 142, no. 7, pp. 1388–1398, 2012.
E. Yoon, A. Babar, M. Choudhary, M. Kutner, and N. Pyrsopoulos, “Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update,” J. Clin. Transl. Hepatol., vol. 4, no. 2, pp. 131–142, 2016, doi: 10.14218/JCTH.2015.00052.
K. J. Heard, “Acetylcysteine for Acetaminophen Poisoning,” New England Journal of Medicine, vol. 359, no. 3, pp. 285–292, 2008, doi: 10.1056/NEJMct0708278.
A. Mallat and S. Lotersztajn, “Endocannabinoids and liver disease,” J. Hepatol., vol. 48, no. 4, pp. 680–688, 2008.
J. Gertsch, M. Leonti, and S. Raduner, “Beta-caryophyllene is a dietary cannabinoid,” Proceedings of the National Academy of Sciences (PNAS), vol. 105, no. 26, pp. 9099–9104, 2008.
A.-L. Klauke, I. Racz, and B. Pradier, “The cannabinoid CB2 receptor-selective phytocannabinoid β-caryophyllene exerts analgesic and anti-inflammatory effects in mice,” European Neuropsychopharmacology, vol. 24, no. 4, pp. 608–620, 2014.
R. S. Mboumba Bouassa, G. Sebastiani, V. Di Marzo, and M. A. Jenabian, “Cannabinoids and Chronic Liver Diseases,” International Journal of Molecular Sciences (IJMS), vol. 23, no. 16, p. 9423, 2022.
J.-H. Cho, H.-J. Chang, S.-K. Lee, H.-J. Kim, J.-K. Hwang, and H.-S. Chun, “Anti-inflammatory effects of β-caryophyllene,” Food and Chemical Toxicology, vol. 45, no. 9, pp. 1751–1758, 2007.
R. G. Pertwee, “Pharmacology of cannabinoid receptors,” Int. J. Obes., vol. 30, no. 1, pp. S13–S18, 2006.
X.-H. A. A. M. Y.-X. B. G.-H. Z. H.-Y. Y. Z.-X. G. E. L. ; X. Z.-X. He, “ beta-Caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms,” Front. Pharmacol., vol. 11, p. 600750, 2021.
Si Chen and JeonKyung Kim., “Evaluation of cannabinoid-induced hepatotoxicity using a human-induced pluripotent stem cell-derived liver organoid,” Sci. Rep., vol. 14, no. 1, p. 1812, 2024.
J. D. Larson et al., “Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip,” Sci. Rep., vol. 15, no. 1, p. 28132, 2025, doi: 10.1038/s41598-025-12846-2.
P. Nagarkatti, R. Pandey, S. A. Rieder, V. L. Hegde, and M. Nagarkatti, “Cannabinoids as anti-inflammatory drugs,” Future Med. Chem., vol. 1, no. 7, pp. 1333–1349, 2009.
H. Jaeschke, Y. Xie, and M. R. McGill, “Acetaminophen-induced Liver Injury: from Animal Models to Humans,” J. Clin. Transl. Hepatol., vol. 2, no. 3, pp. 153–161, 2014, doi: 10.14218/JCTH.2014.00014.
K. L. Hayward, E. E. Powell, K. M. Irvine, and J. H. Martin, “Can paracetamol (acetaminophen) be administered to patients with liver impairment?,” Br. J. Clin. Pharmacol., vol. 81, no. 2, pp. 210–222, 2016, doi: 10.1111/bcp.12802.
W. S. Waring, “Novel acetylcysteine regimens for treatment of paracetamol overdose,” Ther. Adv. Drug Saf., vol. 3, no. 6, pp. 305–315, 2012, doi: 10.1177/2042098612464265.
L. Eadie, L. A. Lo, and M. Boivin, “Clinical guidance for the recognition and management of cannabidiol-associated hepatotoxicity,” Journal of Gastroenterology and Hepatolog, vol. 39, no. 12, pp. 2522–2532, 2024.
J. K. Hemphill, J. C. Turner, and P. G. Mahlberg, “Cannabinoid Content of Individual Plant Organs from Different Geographical Strains of Cannabis sativa L.,” J. Nat. Prod., vol. 43, no. 1, pp. 112–122, 1980.
R. C. Dart and E. Bailey, “Does Therapeutic Use of Acetaminophen Cause Acute Liver Failure?,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 27, no. 9, pp. 1219–1230, 2008, doi: 10.1592/phco.27.9.1219.
A. Wong and A. Graudins, “Risk prediction of hepatotoxicity in paracetamol poisoning,” Clin. Toxicol., vol. 55, no. 8, pp. 879–892, 2017, doi: 10.1080/15563650.2017.1317349.
L. Bader Eddin, A. Mahgoub, S. Almarzooqi, E. Adeghate, S. B. Subramanya, and S. Ojha, “β-Caryophyllene Ameliorates Thioacetamide-Induced Liver Fibrosis in Rats: A Preventative Approach,” Int. J. Mol. Sci., vol. 26, no. 17, p. 8493, 2025, doi: 10.3390/ijms26178493.
V. R. Askari and R. Shafiee-Nick, “Promising neuroprotective effects of β-caryophyllene against LPS-induced oligodendrocyte toxicity: A mechanistic study,” Biochem. Pharmacol., vol. 159, pp. 154–171, 2019, doi: 10.1016/j.bcp.2018.12.001.
R. Dewi, A. Ismail, F. Abas, K. Shaari, and N. H. Lajis, “Acute and subchronic (28-day) oral toxicity studies of beta-caryophyllene in rats,” International Journal of Research in Pharmaceutical Sciences, vol. 5, no. 1, pp. 1–11, 2014.
D. Schmitt, R. Levy, and B. Carroll, “Toxicological evaluation of β-caryophyllene: Toxicity of β-caryophyllene,” Food and Chemical Toxicology, vol. 96, pp. 214–223, 2016.
J. L. Beers, Z. Zhou, and K. D. Jackson, “Translation of In Vitro Cannabidiol-Mediated Inhibition of Human Liver Efflux Transporters to In Vivo Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling,” Drug Metabolism and Disposition, vol. 52, no. 5, pp. 508–515, 2024.
A. R. Da Silveira et al., “Therapeutic potential of beta-caryophyllene against aflatoxin B1-Induced liver toxicity: biochemical and molecular insights in rats,” Chem. Biol. Interact., vol. 348, p. 109635, 2021, doi: 10.1016/j.cbi.2021.109635.
Z. V Varga et al., “β‐Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice,” Br. J. Pharmacol., vol. 175, no. 2, pp. 320–334, 2018, doi: 10.1111/bph.13722.
M. A. Calleja et al., “beta-Caryophyllene ameliorates liver fibrosis and inflammation in mice,” Br. J. Pharmacol., vol. 170, no. 1, pp. 160–178, 2013.
S. Atalay, I. Jarocka-Karpowicz, and E. Skrzydlewska, “Antioxidative and Anti-Inflammatory Properties of Cannabidiol,” Antioxidants, vol. 9, no. 1, p. 21, 2019, doi: 10.3390/antiox9010021.
S. Deiana et al., “Plasma and brain pharmacokinetics of cannabidiol (CBD), cannabidivarin (CBDV), Delta-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) administered orally in mice,” Br. J. Pharmacol., vol. 165, no. 8, pp. 2451–2463, 2012.
C. A. Legare, W. M. Raup-Konsavage, and K. E. Vrana, “Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoids,” Pharmacology, vol. 107, no. 3–4, pp. 131–149, 2022.
A. K. Schlag, C. Hindocha, R. Zafar, D. J. Nutt, and H. V. Curran, “Cannabis based medicinal products: a guide for health professionals,” Br. Med. J., vol. 372, pp. n103–n103, 2021.